Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),

Thomas J. Kipps, M.D., Ph.D, Lode J. Swinnen, MD, William G. Wierda, MD, PhD, Jeffrey Alan Jones, MD, MPH, Steven E. Coutre, MD, Mitchell R Smith, MD, PhD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Sari Enschede, MD, Rod Humerickhouse, MD

Blood (2011) 118 (21): 3904.

https://doi.org/10.1182/blood.V118.21.3904.3904

Published: 2011

Journal Articles

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Thomas J. Kipps, MD, PhD, William G. Wierda, MD, PhD, Jeffrey A. Jones, MD, MPH, Lode J. Swinnen, MD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Andrew Krivoshik, MD, Sari Enschede, MD, Rod Humerickhouse, MD

Blood (2010) 116 (21): 2455.

https://doi.org/10.1182/blood.V116.21.2455.2455

Published: 2010

Journal Articles

Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies

Brad Kahl, MD, Andrew W Roberts, MBBS, PhD, John F Seymour, MD, Ranjana H. Advani, MD, Daniel Oscar Persky, MD, Jianning Yang, PhD, Yue Cui, PhD, Todd Busman, MS, Andrew Krivoshik, MD, Sari Enschede, MD, Rod Humerickhouse, MD

Blood (2010) 116 (21): 3943.

https://doi.org/10.1182/blood.V116.21.3943.3943

Published: 2010

Journal Articles

Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Seong Lin Khaw, MBBS, David C. Huang, MD, PhD, Simon He, MBBS, John F Seymour, MBBS, PhD, Dennis Carney, MBBS, FRACP, FRCPA, Kylie D. Mason, MBBS, PhD, Brenda Chyla, PhD, Elizabeth Litvinovich, MSc, Evelyn McKeegan, PhD, Andrew Krivoshik, MD, PhD, Sari Enschede, MD, Rod Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2009) 114 (22): 2374.

https://doi.org/10.1182/blood.V114.22.2374.2374

Published: 2009

Journal Articles

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Jennifer Brown, MD, PhD, John F. Seymour, M.D., William G. Wierda, M.D., Ph.D, Thomas J. Kipps, MD, PhD, Hao Xiong, Ph.D., Yi-Lin Chiu, PhD, Todd Busman, PhD, Raymond A. Knight, MBA, Sari Enschede, MD, Andrew Krivoshik, MD, PhD, Rod Humerickhouse, MD, PhD

Blood (2008) 112 (11): 3177.

https://doi.org/10.1182/blood.V112.11.3177.3177

Published: 2008

Journal Articles

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Wendy Stock, MD, Karen WL Yee, MD, Eunice S. Wang, MD, Sari Enschede, MD, Joyce Steinberg, MD, Rod Humerickhouse, MD, PhD, Qin Qin, PhD, Jiang Qian, PhD, Yi-Lin Chiu, PhD, Neeraj Gupta, PhD, Rajendra Pradhan, PhD

Blood (2008) 112 (11): 4008.

https://doi.org/10.1182/blood.V112.11.4008.4008

Published: 2008

Journal Articles

Rituximab (Rituxan) Combined with ESHAP Chemotherapy Is Highly Active in Relapsed/ Refractory Aggressive Non-Hodgkin’s Lymphoma.

Parameswaran Venugopal, MD, Stephanie A. Gretory, MD, John Showel, MD, Jamile Shammo, MD, Sari Enschede, MD, Melissa Larson, MD, Teresa Obrien, RN, Tatiana D. Sokolovsky, Aaron Means

Blood (2004) 104 (11): 4636.

https://doi.org/10.1182/blood.V104.11.4636.4636

Published: 2004

Journal Articles

An Attempt to Enhance the Efficacy of Fludarabine, Mitoxantrone, Rituxan (FMR) with GM-CSF Priming: A Phase II Study.

Stacey E. Ban, MD, Parameswaran Venugopal, MD, Jamile M. Shammo, MD, Sari Enschede, MD, Solomon Adler, MD, Teresa O’Brien, RN, Stephanie A. Gregory, MD

Blood (2004) 104 (11): 4829.

https://doi.org/10.1182/blood.V104.11.4829.4829

Published: 2004

NARROW

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL),

Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies

Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

An Ongoing Phase 1 Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Rituximab (Rituxan) Combined with ESHAP Chemotherapy Is Highly Active in Relapsed/ Refractory Aggressive Non-Hodgkin’s Lymphoma.

An Attempt to Enhance the Efficacy of Fludarabine, Mitoxantrone, Rituxan (FMR) with GM-CSF Priming: A Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only